{"id":5280,"date":"2025-09-19T14:16:03","date_gmt":"2025-09-19T10:16:03","guid":{"rendered":"https:\/\/medscriptum.org\/?p=5280"},"modified":"2025-09-19T14:18:02","modified_gmt":"2025-09-19T10:18:02","slug":"roche-is-buying-a-company-that-creates-a-revolutionary-drug-for-treating-liver-diseases-for-3-5-billion","status":"publish","type":"post","link":"https:\/\/medscriptum.org\/en\/roche-is-buying-a-company-that-creates-a-revolutionary-drug-for-treating-liver-diseases-for-3-5-billion\/","title":{"rendered":"Roche is buying a company that creates a revolutionary drug for treating liver diseases for $3.5 billion"},"content":{"rendered":"<p>The pharmaceutical giant <b>Roche<\/b> has announced its plan to acquire the biotechnology company <b>89bio<\/b> for up to $3.5 billion. This decision is driven by Roche&#8217;s interest in a potentially revolutionary drug for liver diseases, called <b>pegozafermin<\/b>.<\/p>\n<p>According to the terms of the deal, Roche will initially pay $2.4 billion, with an additional $1.1 billion to be paid in a series of milestone payments, which will depend on the drug&#8217;s commercial success.<\/p>\n<p>Pegozafermin is a therapy currently in Phase 3 clinical trials, designed to treat patients with metabolic dysfunction-associated steatohepatitis (MASH), including those with non-cirrhotic and compensated cirrhosis. The drug has shown promising results in reducing both liver inflammation and fibrosis.<\/p>\n<p>With this acquisition, Roche significantly strengthens its position in a medical field with a high need for new treatments. The deal is considered a crucial step in the fight against liver and metabolic diseases.<\/p>\n<p>The acquisition is expected to be finalized in the last quarter of 2025.<\/p>\n<p><a href=\"https:\/\/www.biospace.com\/business\/roche-makes-major-mash-move-with-3-5b-89bio-buy\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">BioSpace<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The pharmaceutical giant Roche has announced its plan to acquire the biotechnology company 89bio for up to $3.5 billion. This decision is driven by Roche&#8217;s interest in a potentially revolutionary drug for liver diseases, called pegozafermin. According to the terms of the deal, Roche will initially pay $2.4 billion, with an additional $1.1 billion to [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5279,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1594],"tags":[1953],"class_list":["post-5280","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","tag-roche"],"acf":[],"_links":{"self":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/5280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/comments?post=5280"}],"version-history":[{"count":1,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/5280\/revisions"}],"predecessor-version":[{"id":5285,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/5280\/revisions\/5285"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media\/5279"}],"wp:attachment":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media?parent=5280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/categories?post=5280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/tags?post=5280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}